Squamous cell carcinoma of the head and neck: ESMO clinical recommendations for diagnosis, treatment and follow-up. World Health Organization. National Comprehensive Cancer Network. This site uses cookies. ESMO … JAVELIN Head and Neck 100 is the first randomized, phase 3 study of an immune checkpoint inhibitor combined with CRT in any tumor type. IARC World Cancer Report Updates Learning Platform and Webinars, ESMO Public Policy Track and Special Sessions, ESMO Scale for Clinical Actionability of molecular Targets (ESCAT), Recognition and Status of Medical Oncology, Status of Medical Oncology in Developing Countries, Shortages of Inexpensive, Essential Cancer Medicines, Accessibility and Availability of Medicines, CAREFOR, The Clinical Academic Cancer Research Forum, World Health Organization / United Nations, ESMO responses to European Union and Global Public Consultations, ESMO Gynaecological Cancers Virtual Congress 2021, Molecular Analysis for Precision Oncology Congress 2021, European Lung Cancer Virtual Congress 2021, ESMO Immuno-Oncology Virtual Congress 2020, https://www.who.int/publications-detail/covid-19-operational-guidance-for-maintaining-essential-health-services-during-an-outbreak, https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf, Gastrointestinal cancers: Colorectal cancer (CRC) in the COVID-19 era, Gastrointestinal cancers: Gastro-oesophageal tumours in the COVID-19 era, Gastrointestinal cancers: Pancreatic cancer in the COVID-19 era, Gynaecological malignancies: Epithelial ovarian cancer in the COVID-19 era, Patients experiencing acute toxicities during curative treatment with radiation/systemic therapies, Post-operative patients with complications, Head and neck cancer survivors experiencing signs/symptoms of recurrence, Head and neck cancer survivors experiencing late toxicities, Post-operative or post-(chemo)radiotherapy patients with no complications, Psychological support visits (convert to telemedicine), Patients in early follow-up (first 2 years) after curative treatment, Patients in late follow-up (after 2 years) with neither signs/symptoms of recurrence nor toxicities: refer to telemedicine and postpone imaging, Visits between two treatments for patients on systemic palliative treatment: refer to telemedicine, Prior to any in-person visit, patients should be screened for symptoms of COVID-19 by maximising telemedicine triage and establishing screening at intake by using checklists and monitoring tools, Telemedicine may play a role in primary assessment of signs and symptoms, reassuring anxious subjects, while prompting an urgent in-person visit in case of doubts (new lump in the neck, dysphagia, dyspnoea, minor bleeding…), However, clinical examination of the head and neck via telemedicine for oncological reasons should be avoided except for a general inspection of the neck, face and anterior oral cavity (also in such circumstances, however, it should be noted that palpation and close inspection are the main resources for clinical judgement, especially in already treated patients), Larynx – Hypopharynx: cT3-cT4, every cTN+, rT3-rT4, every rTN+, every patient with instable airway (dyspnoea or pending dyspnoea, dysphagia, painful swallowing, risk of bleeding…), Oral cavity – Oropharynx: cT2-cT4, every cTN+, every patient with instable airway (dyspnoea or pending dyspnoea, dysphagia, painful swallowing, risk of bleeding…), pathological fracture of the mandible, trismus, Paranasal sinuses: cT2-cT4, every cTN+, every patient with diplopia, facial deformity, skin ulceration, frequent and massive oral and/or nose bleeding, Thyroid: cT4, every cT with bulky N+, aggressive histotypes (medullary, tall cell, undifferentiated…), Salivary glands: cT3-cT4, every cTN+, aggressive histotypes (salivary duct, adenoid cystic, high grade mucoepidermoid…), Skin of face and neck: squamous cell carcinomas cT3-cT4 and every cTN+, Every G2-G3 soft tissues or bone sarcomas, Thyroid: cT2-cT3, non-bulky and non-critical N+, Skin of face and neck: squamous cell carcinoma cT1-cT2, large basal cell carcinomas, Skin of face and neck: small basal cell carcinomas, Multidisciplinary team meetings -physically or virtually- should remain the place where clinical choices about curative treatments are mainly defined, High-medium priority patients should not be delayed more than 2 months, Definitive (chemo)radiotherapy for oropharyngeal carcinoma regardless of HPV status and for advanced hypopharyngeal or laryngeal carcinoma, Continuation of treatment in the context of a clinical trial, provided patient benefits outweigh risks, with possible adaptation of procedures without affecting patient safety and study conduct, Postoperative (chemo)radiotherapy for non-in-sano resection/positive margins or extracapsular spread of squamous cell carcinomas, sarcomas, or salivary gland tumours of aggressive histology, Definitive radiotherapy of early glottic cancer (cT1-cT2 N0), Symptomatic palliative treatment (e.g. Monitor. Keytruda’s front-line head and neck cancer trial raises more questions than answers. Debiopharm announces the presentation of the 3-year phase II follow-up data along with 2 posters for xevinapant (antagonist of IAP -Inhibitor of Apoptosis Proteins) and WEE1 inhibitor Debio 0123. Primary brain tumours in the COVID-19 era, Gastrointestinal cancers: Hepatocellular carcinoma (HCC) in the COVID-19 era, Genitourinary cancers: Urothelial cancer of the bladder in the COVID-19 era, Genitourinary cancers: Renal cell cancer in the COVID-19 era, Genitourinary cancers: Prostate cancer in the COVID-19 era, Gynaecological malignancies: Cervical cancer in the COVID-19 era, Gynaecological malignancies: Endometrial cancer in the COVID-19 era, Haematological malignancies: DLBCL, MCL and Aggressive T-cell lymphoma in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Hodgkin lymphoma in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Indolent B-NHL in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Multiple myeloma in the COVID-19 era, Head and neck cancers in the COVID-19 era, COVID-19 adapted recommendations Slide Sets, ESMO-ESO Courses on Medical Oncology for Medical Students, SARS-CoV-2 Vaccination: Special Considerations in Patients with Cancer, ESMO Guidelines: Real World Cases - Live Webinars. To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive. Indication : Head & Neck Cancer. Kalyankrishna S, Grandis JR, Epidermal growth factor receptor biology in head and neck cancer, J Clin Oncol, 2006;24:2666–72. For more detailed information on the cookies we use, please check our Privacy Policy. Testing and Targeting Tumours with RET Alterations, Immune Checkpoint Inhibitors in HNSCC: Changing the Treatment Landscape, Translating Immunity to Clinical Applications of Immunotherapy in Breast Cancer, Past ESMO Partnership, Labelled and Supported Meetings, ESMO Clinical Research Observatory Task Force (ECRO), Acknowledgements: Rationalizing Bureaucracy, Bibliography on Clinical Trial Procedures, ESMO Designated Centres of Integrated Oncology & Palliative Care, Palliative and Supportive Care Sessions at ESMO Asia Virtual Congress 2020, Europe’s Beating Cancer Plan – in 60 minutes. Gregoire V, Lefebvre JL, Licitra L, Felip E, Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 2010;21 Suppl. “Despite today’s current standard of care, high-risk locally-advanced head and neck cancer remains an area of unmet medical need. bleeding, superior cava syndrome, Irradiation of asymptomatic and non-threatening metastases, Local ablative treatment (surgery/stereotactic radiotherapy) of metastases in oligometastatic setting, Steroids should be avoided as much as possible or administered as conservatively as possible, Consider implementing 1-4 fraction regimens for symptomatic palliative cases (e.g. Cancer patient prioritisation. Educate. Scientific investigation is extremely active in the treatment, management, and optimization of therapies for patients with head and neck cancer. All funding for this site is provided directly by ESMO. Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic. 2008 May;19(5):1027-9. Conferences It has become the norm for late-breaking studies highlighted at major medical meetings’ press conferences to be described as “practice-changing”, and at Esmo today this accolade was bestowed on Merck & Co’s Keynote-048 trial of Keytruda in first-line head and neck cancer. Slides and webcasts from all ESMO Preceptorship courses are open to all with at least a free ESMO account, according to the presenters' agreement to release them. In a phase 3 trial, the med only extended second-line head and neck cancer patients’ lives by 8.4 months, compared with the 7.1 months achieved with standard treatment. Receive information and updates on ESMO’s scientific and educational resources, events, members activities. JAVELIN HEAD AND NECK 100 results at ESMO 2020. In this presentation, Angela Fischer Maranta, KSGR, Chur covers the most important findings from the ESMO virtual meeting 2020 for the topic Head and Neck. Primary brain tumours in the COVID-19 era, Gastrointestinal cancers: Hepatocellular carcinoma (HCC) in the COVID-19 era, Genitourinary cancers: Urothelial cancer of the bladder in the COVID-19 era, Genitourinary cancers: Renal cell cancer in the COVID-19 era, Genitourinary cancers: Prostate cancer in the COVID-19 era, Gynaecological malignancies: Cervical cancer in the COVID-19 era, Gynaecological malignancies: Endometrial cancer in the COVID-19 era, Haematological malignancies: DLBCL, MCL and Aggressive T-cell lymphoma in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Hodgkin lymphoma in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Indolent B-NHL in the second phase of the COVID-19 pandemic (ESMO-EHA), Haematological malignancies: Multiple myeloma in the COVID-19 era, Head and neck cancers in the COVID-19 era, COVID-19 adapted recommendations Slide Sets, ESMO-ESO Courses on Medical Oncology for Medical Students, SARS-CoV-2 Vaccination: Special Considerations in Patients with Cancer, ESMO Guidelines: Real World Cases - Live Webinars. risk of fracture or bleeding, Irradiation of symptomatic metastases (depending on symptoms and availability of radiotherapy resources): e.g. Service providers (head and neck cancer secondary and tertiary care services) have systems in place for people with N3 upper aerodigestive tract cancer or T4 cancers of the hypopharynx and nasopharynx to have systemic staging using FDG PET-CT. PracticeUpdate: How was this trial designed? PracticeUpdate Editorial Team Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly. Although the 19% improvement in overall survival among patients treated with … At ESMO this year we heard the results of JAVELIN Head and Neck 100 presented by Ezra Cohen from UCSD. Available at: https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf (26th August 2020, date last accessed). ESMO Virtual Preceptorship on Head and Neck Cancer 2020. Meeting Coverage > ESMO Neoadjuvant IO Yields Deep Responses in Head and Neck Cancer — One-third of patients achieved "near" pCR in phase I/II trial Thomson DJ, Palma D, Guckenberger M et al. Practice recommendations for risk-adapted head and neck cancer radiation therapy during the COVID-19 pandemic: An ASTRO-ESTRO Consensus Statement. 4. Necessary cookies enable core functionality. Coronavirus Disease 2019 (COVID-19) Resources for the Cancer Care Community. Available at: https://www.who.int/publications-detail/covid-19-operational-guidance-for-maintaining-essential-health-services-during-an-outbreak (1st September 2020, date last accessed). For more detailed information on the cookies we use, please check our Privacy Policy. There have been a number of large trials that have completed accrual, and that we have been waiting for the results of. Last weekend (April 13-14, 2019), I was very fortunate to have had the opportunity of participating at the European Society of Medical Oncology (ESMO) Head and Neck Cancer Preceptorship Programme held at Kowloon, Hong Kong. Debiopharm to Present Late Breaking Head & Neck Cancer Abstract at the 2020 European Society Of Medical Oncology Congress. MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23. Abstract No : Presentation 910O. 030 - 899 06 65 secretariaat@nvmo.org Supportive care during radiotherapy with/without systemic therapy: Consider replacing weekly on-site patient reviews with video- or telephone-consultations, Early initiation of systemic therapy in patients with fast disease pace, high tumour burden and/or symptomatic, Initiation of systemic therapy in patients with less aggressive disease features, Monotherapy (e.g. NCCN Guidelines Head and Neck Cancers Version 2.2020. Will Recent Major Trials With CDK Inhibitors Be Practice Changing In Early Breast Cancer? capecitabine), when feasible, might be offered to avoid frequent access to hospital, Tracheotomy in case of obstruction of the upper airways/stridor, Threatening lesion, e.g. SCC (90%) What is the preferred imaging study in HNSCC? ESMO management and treatment adapted recommendations in the COVID-19 era: Head and Neck Cancers, ESMO Facebook Roundtable: COVID-19 Vaccines and Cancer Care - The known, the unknown and the unknowable, ESMO Facebook Roundtable: COVID-19 vs Cancer - Reorganising cancer care after the first wave, ESMO Facebook Roundtable: COVID-19 vs Cancer - The future of cancer research, ESMO Facebook Roundtable: COVID-19 vs Cancer - Weighing up risks over time, Cancer Patient Management During the COVID-19 Pandemic, COVID-19 and cancer care in the ESMO journals, From ESMO Vision 2020 to ESMO Vision 2025, Adolescents and Young Adults Working Group, ESMO SIOG Cancer in the Elderly Working Group, Examination & Accreditation Working Group, Translational Research and Precision Medicine Working Group, Magnitude of Clinical Benefit Scale Working Group, Press and Media Affairs Committee and Social Media Working Group.